Back to Browse Journals » International Journal of Nanomedicine » Volume 1 » Issue 4

Nanocrystalline silver dressings in wound management: a review

Authors Joy Fong, Fiona Wood

Published 15 January 2007 Volume 2006:1(4) Pages 441—449

Joy Fong1, Fiona Wood2
1Burns Unit, Burns Service, Royal Perth Hospital, west Australia 2Burns Service, Royal Perth Hospital/Princess Margaret Hospital, west Australia
Abstract: This paper describes the properties of nanocrystalline silver products (Acticoat™) and their applications and examines available evidence supporting their use in wound management. Acticoat utilizes nanotechnology to release nanocrystalline silver crystals. Acticoat releases 30 times less silver cations than silversulfadiazine cream or 0.5% silver nitrate solution but more of the silver released (by Acticoat). Silver-impregnated slow-release dressings release minute concentrations of silver which are quickly bound up by the chloride in the wound exudate. While extrapolations from in vitro and animal studies are cautious, evidence from these studies suggests Acticoat is: effective against most common strains of wound pathogens; can be used as a protective covering over skin grafts; has a broader antibiotic spectrum activity; and is toxic to keratinocytes and fibroblasts. Animal studies suggest a role for nanocrystalline silver in altering wound inflammatory events and facilitation of the early phase of wound healing. Quality human clinical trials into nanocrystalline silver are few. However, evidence suggests using Acticoat in wound management is cost effective, reduces wound infection, decreases the frequency of dressing changes and pain levels, decreases matrix metalloproteinase activity, wound exudate and bioburden levels, and promotes wound healing in chronic wounds. Although there is no in vivo evidence to suggest nanocrystalline silver is toxic to human keratinocytes and fibroblasts, there is in vitro evidence to suggest so; thus these dressings should be used cautiously over epithelializing and proliferating wounds. Future clinical research, preferably randomized controlled trials into nanocrystalline silver technology, may provide clinicians a better understanding of its applications in wound management.
Keywords: nanocrystalline, silver, burns, chronic, wounds, dressings

Download Article [PDF] 

Readers of this article also read:

Anemia associated with chronic heart failure: current concepts

Shah R, Agarwal AK

Clinical Interventions in Aging 2013, 8:111-122

Published Date: 4 February 2013

Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease

Crowther RG, Leicht AS, Spinks WL, Sangla K, Quigley F, Golledge J

Vascular Health and Risk Management 2012, 8:225-232

Published Date: 17 April 2012

Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells

Dolman MEM, Harmsen S, Pieters EHE, Sparidans RW, Lacombe M, Szokol B, Őrfi L, Kéri G, Storm G, Hennink WE, Kok RJ

International Journal of Nanomedicine 2012, 7:417-433

Published Date: 31 January 2012

Descemet's stripping automated endothelial keratoplasty for congenital hereditary endothelial dystrophy

Anwar HM, El Danasoury AM, Hashem AN

Clinical Ophthalmology 2012, 6:159-163

Published Date: 24 January 2012

New methodologies to characterize the effectiveness of the gene transfer mediated by DNA-chitosan nanoparticles

Miguel N Centelles, Cheng Qian, Miguel A Campanero, Juan M Irache

International Journal of Nanomedicine 2008, 3:451-460

Published Date: 5 December 2008

Connective tissue progenitor cell growth characteristics on textured substrates

Alvaro Mata, Cynthia Boehm, Aaron J Fleischman, George F Muschler, Shuvo Roy

International Journal of Nanomedicine 2007, 2:389-406

Published Date: 15 October 2007

Valsartan in the treatment of heart attack survivors

Bodh I Jugdutt

Vascular Health and Risk Management 2006, 2:125-138

Published Date: 15 June 2006